Moomoo AI 已提取核心信息
ADIMAB, LLC, a 10% stockholder in Invivyd, Inc., is set to sell 5,000,000 shares of common stock on January 19, 2024. The shares, with an aggregate market value of $19,750,000, were originally acquired on August 6, 2021, through a private acquisition from the issuer. The acquisition was made in cash for a total of 26,687,906 shares. There have been no reported sales of securities by ADIMAB, LLC in the past three months.
ADIMAB, LLC, a 10% stockholder in Invivyd, Inc., is set to sell 5,000,000 shares of common stock on January 19, 2024. The shares, with an aggregate market value of $19,750,000, were originally acquired on August 6, 2021, through a private acquisition from the issuer. The acquisition was made in cash for a total of 26,687,906 shares. There have been no reported sales of securities by ADIMAB, LLC in the past three months.
ADIMAB, LLC是Invivyd, Inc. 10％的股东，定于2024年1月19日出售500万股普通股。这些股票的总市值为19,750,000美元，最初于2021年8月6日通过发行人的私下收购收购。此次收购以现金进行，共计26,687,906股。在过去的三个月中，没有关于ADIMAB, LLC出售证券的报告。
ADIMAB, LLC是Invivyd, Inc. 10％的股东，定于2024年1月19日出售500万股普通股。这些股票的总市值为19,750,000美元，最初于2021年8月6日通过发行人的私下收购收购。此次收购以现金进行，共计26,687,906股。在过去的三个月中，没有关于ADIMAB, LLC出售证券的报告。
有用
没用
